RxDoctor Payments Data

Michael Rivera, DPM

Foot & Ankle Surgery · Pembroke Pines, FLNPI 1528079787

Payments from drug & device makers

$34,097in general payments, 2019–2025

Across 146 payments — averaging $233.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Organogenesis Inc.$13K
  • HNM Stainless, LLC$5K
  • In2bones USA, LLC$3K
  • Southern Edge Orthopaedics, Inc.$3K
  • Treace Medical Concepts, Inc.$3K
  • Paragon 28, Inc.$2K
  • plus $6K from 23 others

What the payments were for

  • Consulting fees$4,48813%
  • Speaking & faculty fees$1,5004%
  • Travel & lodging$2,2977%
  • Food & beverage$10,40131%
  • Education$2,6618%
  • Other$12,75037%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$34,097 in reported general payments places this provider in the 90th percentile of 850 foot & ankle surgery providers in Florida.

See all foot & ankle surgery providers in Florida

Medicare billing

Part B allowed, 2024
$62,080
Medicare patients
101
Services billed
816

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.12$3,545
Celecoxib41$1,748
Ammonium Lactate20$403
Meloxicam113$294
Ketoconazole16$252
Terbinafine Hcl14$242
Mupirocin44$227
Vitamin D2Ergocalciferol (Vitamin D2)18$98
Cephalexin14$57
Ciprofloxacin Hcl11$41

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$209$3,54512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 850 foot & ankle surgery providers in Florida.

Other foot & ankle surgery in Pembroke Pines

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →